Novo Nordisk Committed To Advancing In Cardiovascular

As Ziltivekimab Shows Promise

20 Sep 2022

The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.

Martin Lange — Martin Holst Lange • Source: Novo Nordisk

Best-known as the world's largest diabetes company, it made sense that Novo Nordisk A/S would increase its research efforts in the cardiovascular space, building on its learnings over the past decade.

So said head of development Martin Holst Lange in an interview with Scrip after the doors closed on the recent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

06 Aug 2025

• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

31 Jul 2025

• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

25 Jul 2025

• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Novartis Upbeat Even With Entresto Expiry Looming

17 Jul 2025

• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA)

06 Aug 2025

• By Alaric DeArment

The news will have a big impact on pandemic preparedness but less immediate financial impact. Tiba Biotech was even “caught off guard” by its inclusion in the department’s culling of mRNA vaccine projects under BARDA, as its project was neither a vaccine nor mRNA-based.